About |
Lugano, Switzerland, March 05th 2014. The MASCC Antiemesis Tool (MAT) is the first application for cancer patients receiving chemotherapy that assists healthcare professionals in evaluating if, and how much the anti-cancer treatment is causing nausea and vomiting.
Patients fighting cancer may experience chemotherapy-induced nausea and vomiting, potential side effects that may impact their quality of life. The MAT was developed by the Multinational Association for Supportive Care in Cancer, to assist patients and oncology professionals in communicating accurately about the prevention and control of nausea and vomiting that may occur with chemotherapy. The concept of the MAT is to provide an easy to use tool, that will assist in providing the best individual care for patients.
The MAT tool includes questions regarding the intensity and frequency of nausea and vomiting after chemotherapy; during the first 24 hours, and up to 4 days after chemotherapy.
After completing the MAT from a smartphone or a tablet, patients may send their responses to their physicians or nurses in real time. Health care professionals can promptly follow up, and manage symptoms if necessary.
MAT is free and it is available in English, French, Italian, German and Spanish. The printable version of the questionnaire is available on the MASCC website (www.mascc.org) in English as well as in 11 languages: Arabic, French, German, Greek, Italian, Japanese, Korean, Portuguese, Serbian, Spanish, Turkish.
The MAT Tool is supported by an unrestricted grant form Helsinn Healthcare S.A..
Watch the app presentation on Videum and learn more at antiemesistool.com
Download MAT Tool on App Store, Google Play.
The App MAT Tool can also be directly downloaded from the MASCC website.
Developers
The MASCC Antiemesis Tool (MAT) was developed by members of MASCC.
The group primarily responsible for the development of the tool was composed of nurses, pharmacists, and physicians. These include:
• Sussanne Borjeson, RN, PhD
• Rebecca Clark-Snow, RN, BSN
• Rebecca Finley, PharmD, MS
• Richard J. Gralla, MD
• Mark G. Kris, MD
• Cynthia N. Rittenberg, RN, MN
This questionnaire is further validated by Prof. Molassiotis et al, see the scientific publication at http://www.ncbi.nlm.nih.gov/pubmed/17509816.